The pharmaceutics and delivery of therapeutic polypeptides and proteins
暂无分享,去创建一个
[1] T. Blankenstein,et al. Lack of tumorigenicity of interleukin 4 autocrine growing cells seems related to the anti-tumor function of interleukin 4. , 1990, Molecular immunology.
[2] D. Niederwieser,et al. Rapid reappearance of large granular lymphocytes (LGL) with concomitant reconstitution of natural killer (NK) activity after human bone marrow transplantation (BMT) , 1987, British journal of haematology.
[3] T. Back,et al. Successful treatment of advanced murine renal cell cancer by bicompartmental adoptive chemoimmunotherapy. , 1987, Journal of immunology.
[4] J. Yannelli,et al. IL-2 and Cellular Therapy:Lymphokine-Activated Killer Cells and Tumor-Derived Activated Cells , 1990 .
[5] F. Mandelli,et al. Severe deficiency of natural killer activity in the peripheral blood of patients with hairy cell leukemia. , 1983, Blood.
[6] H. Deeg,et al. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts , 1985 .
[7] M. O’connell,et al. Remissions in hairy-cell leukemia with pentostatin (2'-deoxycoformycin). , 1987, The New England journal of medicine.
[8] H. Volk,et al. Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer , 1991, The Journal of experimental medicine.
[9] A. Landay,et al. CHARACTERIZATION OF CIRCULATING SUPPRESSOR T LYMPHOCYTES IN BONE MARROW TRANSPLANT RECIPIENTS , 1987, Transplantation.
[10] Fierros Le,et al. The drops of life. I.V. therapy as a nursing responsibility. , 1970 .
[11] Jaap M Middeldorp,et al. Recovery of T cell subsets after autologous bone marrow transplantation is mainly due to proliferation of mature T cells in the graft. , 1985, Blood.
[12] R. Spiegel,et al. Alfa-2b interferon in the treatment of Hodgkin's disease and non-Hodgkin's lymphoma. , 1987, Seminars in oncology.
[14] D. Crowther,et al. In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients. , 1988, British Journal of Cancer.
[15] A. Hess,et al. Development of graft-vs.-host disease-like syndrome in cyclosporine- treated rats after syngeneic bone marrow transplantation. I. Development of cytotoxic T lymphocytes with apparent polyclonal anti-Ia specificity, including autoreactivity , 1985, The Journal of experimental medicine.
[16] M. Sznol,et al. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen. , 1990, Cancer research.
[17] A. Rimm,et al. Graft-versus-leukaemia reactivity induced by alloimmunisation without augmentation of graft-versus-host reactivity , 1979, Nature.
[18] S. Rosenberg,et al. Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A. Ho,et al. Clinical implications of increased plasma levels of CD8 in patients with hairy cell leukemia. , 1990, Blood.
[20] S. Rosenberg,et al. Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues. , 1985, Journal of immunology.
[21] T. Phillips,et al. Recombinant leukocyte A interferon in B-cell chronic lymphocytic leukemia: in vivo effects on autologous antitumor immunity. , 1985, Journal of biological response modifiers.
[22] M. Wadhwa,et al. In vivo administration of interleukin 2 stimulates mitosis in thymus and bone marrow , 1986, European journal of immunology.
[23] D. Golde,et al. Therapy for neutropenia in hairy cell leukemia with recombinant human granulocyte colony-stimulating factor. , 1988, Annals of internal medicine.
[24] M. Ratain,et al. Report of a multi-institutional study of 193 patients with hairy cell leukemia treated with interferon-alfa2b. , 1988, Seminars in oncology.
[25] J. Apperley,et al. GENE THERAPY: CURRENT STATUS AND FUTURE DIRECTIONS , 1990, British journal of haematology.
[26] P. Debré,et al. Factor requirements activation and proliferation steps of human cd2+cd3−cd4−cd8− early thymocytes , 1989, European journal of immunology.
[27] K. Orita,et al. Application of an interleukin 2 slow delivery system to the immunotherapy of established murine colon 26 adenocarcinoma liver metastases. , 1990, Cancer research.
[28] T. Sayers,et al. Antitumor Effects of α-Interferon and γ-Interferon on a Murine Renal Cancer (Renca) in Vitro and in Vivo , 1990 .
[29] M. Grever,et al. Treatment of hairy cell leukemia: the Ohio State University experience with deoxycoformycin. , 1987, Leukemia.
[30] H. Deeg,et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. , 1986, The New England journal of medicine.
[31] S. Asano,et al. ACCELERATION OF NEUTROPHILIC GRANULOCYTE RECOVERY AFTER BONE-MARROW TRANSPLANTATION BY ADMINISTRATION OF RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR , 1988, The Lancet.
[32] W. Hryniuk,et al. The importance of dose intensity in chemotherapy of metastatic breast cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] H. Deeg,et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. , 1986, Blood.
[34] R. Herberman,et al. Rationale for recombinant human interferon-gamma adjuvant immunotherapy for cancer. , 1988, Journal of the National Cancer Institute.
[35] O. Vos. MULTIPLICATION OF HAEMOPOIETIC COLONY FORMING UNITS (CFU) IN MICE AFTER X‐IRRADIATION AND BONE MARROW TRANSPLANTATION , 1972, Cell and tissue kinetics.
[36] M. Harada,et al. Administration of human urinary colony stimulating factor after bone marrow transplantation. , 1988, Bone marrow transplantation.
[37] R. Fisher,et al. A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] P. Volberding,et al. Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. , 1984, Annals of internal medicine.
[39] D. S. Coffey,et al. Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II. , 1987, Cancer research.
[40] H. Ozer,et al. B cell growth factor-induced proliferation of hairy cell lymphocytes and inhibition by type I interferon in vitro. , 1986, Blood.
[41] L. Old,et al. Tumor necrosis factor (TNF). , 1985, Science.
[42] S. Orkin,et al. Phenotype of recovering lymphoid cell populations after marrow transplantation , 1985, The Journal of experimental medicine.
[43] T. Merigan,et al. Human interferon alpha in malignant lymphoma and Hodgkin's disease. Results of the american cancer society trial , 1985, Cancer.
[44] D. Kaplan,et al. In vivo activity of solid phase interleukin 2. , 1991, Cancer research.
[45] S. Litwin,et al. A phase I study of recombinant interleukin 2 plus recombinant beta-interferon. , 1988, Cancer research.
[46] R. Geller,et al. Successful in vitro graft-versus-tumor effect against an Ia-bearing tumor using cyclosporine-induced syngeneic graft-versus-host disease in the rat. , 1989, Blood.
[47] E. Cronkite,et al. Post-Radiation Parabiosis and Survival in Rats.∗ , 1951, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[48] K. Atkinson,et al. Reconstruction of the haemopoietic and immune systems after marrow transplantation. , 1990, Bone marrow transplantation.
[49] E. Hersh,et al. A phase I study of therapy with recombinant granulocyte-macrophage colony-stimulating factor administered by IV bolus or continuous infusion. , 1988, Behring Institute Mitteilungen.
[50] W. Hryniuk. More is better. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] E. Gilboa,et al. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity , 1990, The Journal of experimental medicine.
[52] M. Levine,et al. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] L. Lum. The kinetics of immune reconstitution after human marrow transplantation. , 1987, Blood.
[54] F. Herrmann,et al. Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] N. Minato,et al. IL-7 promotes thymocyte proliferation and maintains immunocompetent thymocytes bearing alpha beta or gamma delta T-cell receptors in vitro: synergism with IL-2. , 1989, Journal of immunology.
[56] J. Thompson,et al. Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] M. Socinski,et al. GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR EXPANDS THE CIRCULATING HAEMOPOIETIC PROGENITOR CELL COMPARTMENT IN MAN , 1988, The Lancet.
[58] A. Huang,et al. A randomized comparison of two doses of human lymphoblastoid interferon- alpha in hairy cell leukemia. Wellcome HCL Study Group , 1991 .
[59] M. Ratain,et al. Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] J. Talmadge. Biological response modifiers: realizing their potential in cancer therapeutics , 1986 .
[61] S. Russell,et al. Immunity to B16 melanoma in mice immunized with IL‐2‐secreting allogeneic mouse fibroblasts expressing melanoma‐associated antigens , 1992, International journal of cancer.
[62] T. Tötterman,et al. Regeneration of functional and activated NK and T sub-subset cells in the marrow and blood after autologous bone marrow transplantation: a prospective phenotypic study with 2/3-color FACS analysis. , 1989, Leukemia.
[63] R. Miller,et al. Clonal analysis of T-cell deficiencies in autotransplant recipients. , 1991, Blood.
[64] G. Keller,et al. Expression of a foreign gene in myeloid and lymphoid cells derived from multipotent haematopoietic precursors , 1985, Nature.
[65] S. Perry,et al. Hemopoietic stem cells in human peripheral blood , 1975, Science.
[66] A. Mazumder,et al. Successful therapy of natural killer-resistant pulmonary metastases by the synergism of gamma-interferon with tumor necrosis factor and interleukin-2 in mice. , 1988, Cancer research.
[67] Eliane Gluckman,et al. Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival. , 1989 .
[68] T. Boone,et al. Disulfide and secondary structures of recombinant human granulocyte colony stimulating factor. , 1989, Archives of biochemistry and biophysics.
[69] A. Asher,et al. Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors. , 1991, Journal of immunology.
[70] J. Bubeník,et al. Immunotherapy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2. , 1990, Immunology letters.
[71] W. Paul,et al. Interleukin 2 induces antigen-reactive T cell lines to secrete BCGF-I , 1983, The Journal of experimental medicine.
[72] J. Talmadge,et al. Immunomodulatory and immunotherapeutic properties of recombinant gamma-interferon and recombinant tumor necrosis factor in mice. , 1987, Cancer research.
[73] J. Ajani,et al. Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer. , 1989, Cancer research.
[74] R. Storb,et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. , 1979, The New England journal of medicine.
[75] H. Tilg,et al. Comparison of clinical efficacy and toxicity of conventional and optimum biological response modifying doses of interferon alpha-2C in the treatment of hairy cell leukemia: a retrospective analysis of 39 patients. , 1989, Leukemia.
[76] S. Broder,et al. Subcutaneous recombinant granulocyte-macrophage colony-stimulating factor used as a single agent and in an alternating regimen with azidothymidine in leukopenic patients with severe human immunodeficiency virus infection. , 1990, Blood.
[77] L. V. van Putten,et al. Pathologic changes in irradiated monkeys treated with bone marrow. , 1961, Journal of the National Cancer Institute.
[78] M. Ratain,et al. Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia. , 1990, Blood.
[79] G. Keller,et al. Clonal fluctuation within the haematopoietic system of mice reconstituted with retrovirus‐infected stem cells. , 1987, The EMBO journal.
[80] J. Willson,et al. Phase II Trial of a Combination of Interferon-βser and Interferon-γ in Patients with Advanced Malignant Melanoma , 1988 .
[81] A. C. Dubbelman,et al. A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects. , 1992, British Journal of Cancer.
[82] J. Goldman,et al. Transfusion of circulating stem cells. , 1984, Critical reviews in clinical laboratory sciences.
[83] T. Malinin,et al. PERIPHERAL LEUKOCYTE INFUSION INTO LETHALLY IRRADIATED GUINEA PIGS. , 1965, Blood.
[84] R. Vollmer,et al. Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. , 1989, Journal of the American Academy of Dermatology.
[85] S. Miyatake,et al. Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[86] A. Ghosh,et al. Lack of correlation between peripheral blood lymphokine‐activated killer (lak) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2 , 1989, International journal of cancer.
[87] J. Gutterman,et al. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity. , 1988, Cancer research.
[88] F. Sigaux,et al. c-myc and c-fos expression during interferon-alpha therapy for hairy cell leukemia. , 1986, Blood.
[89] K. Eguchi,et al. Three Schedules of Recombinant Human Interleukin‐2 in the Treatment of Malignancy: Side Effects and Immunologic Effects in Relation to Serum Level , 1988, Japanese journal of cancer research : Gann.
[90] R. Bast,et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. , 1988, The New England journal of medicine.
[91] M. Baseler,et al. ANTI-RETROVIRAL EFFECTS OF INTERFERON-α IN AIDS-ASSOCIATED KAPOSI'S SARCOMA , 1988, The Lancet.
[92] H. Heslop,et al. Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders , 1990, The Journal of experimental medicine.
[93] A. Komiyama,et al. Increases in neutrophil counts by purified human urinary colony-stimulating factor in chronic neutropenia of childhood. , 1988, Blood.
[94] C. Eaves,et al. Retroviral gene transfer to primitive normal and leukemic hematopoietic cells using clinically applicable procedures. , 1992, The Journal of clinical investigation.
[95] Jean E. Sanders,et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. , 1988, Blood.
[96] J. Gutterman,et al. Effect of recombinant granulocyte/macrophage colony-stimulating factor on human monocyte activity in vitro and following intravenous administration. , 1988, Cancer research.
[97] David A. Williams,et al. Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse , 1984, Nature.
[98] J. Ritz,et al. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. , 1992, Blood.
[99] H. Maguire,et al. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. , 1984, Cancer research.
[100] J. Griffin. Hemopoietins in oncology: factoring out myelosuppression. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[101] T. Whiteside,et al. Recombinant human granulocyte/macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor alpha and interferon in cancer patients. , 1989, Blood.
[102] R. Hoffman,et al. Recombinant GM-CSF/IL-3 fusion protein: its effect on in vitro human megakaryocytopoiesis. , 1992, Experimental hematology.
[103] H. Golomb,et al. Treatment options for hairy-cell leukemia. , 1991, Seminars in oncology.
[104] J. Gabrilove,et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. , 1988, The New England journal of medicine.
[105] W. Farrar,et al. Regulation of the production of immune interferon and cytotoxic T lymphocytes by interleukin 2. , 1981, Journal of immunology.
[106] S. Rosenberg,et al. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells. , 1985, Journal of immunology.
[107] D. Olive,et al. Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. , 1990, Blood.
[108] K. Eguchi,et al. Phase I study of combination therapy with interleukin 2 and beta-interferon in patients with advanced malignancy. , 1989, Cancer research.
[109] J. Manning,et al. Alpha interferon for induction of remission in hairy-cell leukemia. , 1984, The New England journal of medicine.
[110] M. Moore,et al. Accelerated recovery of peripheral blood cell counts in mice transplanted with in vitro cytokine-expanded hematopoietic progenitors. , 1992, Experimental hematology.
[111] M. Toribio,et al. A role for interleukin 4 in the differentiation of mature T cell receptor gamma/delta + cells from human intrathymic T cell precursors , 1990, The Journal of experimental medicine.
[112] W. M. Linehan,et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.
[113] E. Tomlinson. Impact of the new biologies on the medical and pharmaceutical sciences. , 1992, The Journal of pharmacy and pharmacology.
[114] D. Reece,et al. Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse [corrected]. , 1991, Blood.
[115] W. McBride,et al. Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity. , 1992, Cancer research.
[116] A. Waheed,et al. Demonstration of a blood-bone marrow barrier to macrophage colony-stimulating factor. , 1989, Blood.
[117] M. Chilosi,et al. Alpha-interferon activates the natural killer system in patients with hairy cell leukemia , 1986 .
[118] Ihor R. Lemischka,et al. Developmental potential and dynamic behavior of hematopoietic stem cells , 1986, Cell.
[119] S. Piantadosi,et al. INDUCTION OF GRAFT-VERSUS-HOST DISEASE AFTER AUTOLOGOUS BONE MARROW TRANSPLANTATION , 1989, The Lancet.
[120] A. Chang,et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. , 1985, The New England journal of medicine.
[121] A. Porgador,et al. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. , 1992, Cancer research.
[122] R. Humphries,et al. Gene transfer to primary normal and malignant human hemopoietic progenitors using recombinant retroviruses. , 1987, Blood.
[123] H. Müller-Hermelink,et al. Bone marrow transplantation in rats across strong histocompatibility barriers by selective elimination of lymphoid cells in donor marrow. , 1976, Transplantation proceedings.
[124] J. Quesada,et al. Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma. , 1988, Journal of biological response modifiers.
[125] S. Medendorp,et al. Phase I Clinical Trial of Interleukin 2 and α-Interferon: Toxicity and Immunologic Effects , 1989 .
[126] S. Seeber,et al. A prospective randomized comparison of single‐agent interferon (IFN)‐alpha with the combination of IFN‐alpha and low‐dose IFN‐gamma in chronic myelogenous leukaemia , 1992, European journal of haematology.
[127] R. Herberman. Clinical cancer therapy with IL-2. , 1989, Cancer investigation.
[128] A. Scarpa,et al. Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of recombinant alpha-interferon therapy on clinical parameters and natural killer in vitro activity. , 1987, Blood.
[129] J. Kirkwood,et al. Interferon alpha in combination with other biologics: the scientific rationale , 1991, British journal of haematology.
[130] K. Sullivan,et al. Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation. , 1987, Annals of internal medicine.
[131] J. Dick,et al. Gene transfer into normal human hematopoietic cells using in vitro and in vivo assays. , 1991, Blood.
[132] A. Burgess,et al. Pharmacokinetics of human granulocyte-macrophage colony-stimulating factor using a sensitive immunoassay. , 1988, Blood.
[133] A. Kimchi. Increased levels of interferon-induced (2'--5') oligo-isoadenylate synthetase in mature T-lymphocytes and in differentiated Friend-erythroleukemic cells. , 1981, Journal of interferon research.
[134] D. Longo,et al. Phase II trial of recombinant leukocyte A interferon in patients with advanced chronic lymphocytic leukemia. , 1985, The American journal of medicine.
[135] I. Tannock,et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[136] R. Elashoff,et al. Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial. , 1986, Annals of internal medicine.
[137] H. Muss,et al. Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[138] L. Kanz,et al. Combination of cytokines: current status and future prospects , 1991, British journal of haematology.
[139] H. Klingemann,et al. Immunotherapy after bone marrow transplantation. , 1991, Bone marrow transplantation.
[140] R. Freidinger,et al. Non-peptide ligands for peptide receptors. , 1989, Trends in pharmacological sciences.
[141] A. Zipursky,et al. Leukemic reticuloendotheliosis. A failure of monocyte production. , 1976, The New England journal of medicine.
[142] A. Ganser,et al. In vitro and in vivo action of recombinant human GM-CSF (rhGM-CSF) in patients with myelodysplastic syndromes. , 1988, Blood cells.
[143] J. Dick,et al. Introduction of a selectable gene into primitive stem cells capable of long-term reconstitution of the hemopoietic system of W/Wv mice , 1985, Cell.
[144] S. Groshen,et al. Induction of graft versus leukemia effect in bone marrow transplantation: dosage and time schedule dependency of interleukin 2 therapy. , 1991, Cancer research.
[145] R. Kurzrock,et al. Phase I study of a combination of recombinant interferon-alpha and recombinant interferon-gamma in cancer patients. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[146] J. Quesada,et al. Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[147] E. Tomlinson. Control of the Biological Dispersion of Therapeutic Proteins , 1990 .
[148] S. Salmon,et al. Effects of cloned human leukocyte interferons in the human tumor stem cell assay. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[149] Chronic B-lymphocytic leukemia cells proliferate and differentiate following exposure to interferon in vitro. , 1986 .
[150] J. Blay,et al. Generation of lymphokine-activated killer cells: synergy between tumor necrosis factor and interleukin 2. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[151] A. Rimm,et al. Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.
[152] J. Groopman,et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. , 1987, The New England journal of medicine.
[153] H. Micklem,et al. Limited potential of circulating haemopoietic stem cells , 1975, Nature.
[154] J. Loutit,et al. HÆMOPOIETIC STEM CELLS IN THE PERIPHERAL BLOOD , 1967 .
[155] S. Reed,et al. Recombinant interleukin 7, pre-B cell growth factor, has costimulatory activity on purified mature T cells , 1989, The Journal of experimental medicine.
[156] J. Talmadge,et al. Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease. , 1987, Cancer research.
[157] R. Puri,et al. Interleukin-2 toxicity. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[158] B. Aggarwal,et al. Characterization of receptors for human tumour necrosis factor and their regulation by γ-interferon , 1985, Nature.
[159] R Storb,et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. , 1989, Blood.
[160] D. Crowther,et al. Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions--a phase I dose-toxicity study. , 1989, British Journal of Cancer.
[161] D. Goeddel,et al. Effect of interleukin 2, interferon-gamma, and mitogens on the production of tumor necrosis factors alpha and beta. , 1985, Journal of immunology.
[162] L. Lum. Immune recovery after bone marrow transplantation. , 1990, Hematology/oncology clinics of North America.
[163] D. Catovsky,et al. Cryopreserved peripheral blood cells functioning as autografts in patients with chronic granulocytic leukaemia in transformation. , 1979, British medical journal.
[164] Jeffrey W. Clark,et al. Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia , 1988 .
[165] P. Sideras,et al. Recombinant interleukin 4/BSF‐1 promotes growth and differentiation of intrathymic T cell precursors from fetal mice in vitro. , 1987, The EMBO journal.
[166] Z. Maricić,et al. APPLICATION OF HUMAN LEUCOCYTE INTERFERON IN PATIENTS WITH URINARY BLADDER PAPILLOMATOSIS, BREAST CANCER, AND MELANOMA , 1981, The Lancet.
[167] J. Reuben,et al. Treatment of acquired immunodeficiency syndrome--related Kaposi's sarcoma with lymphoblastoid interferon. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[168] M. Palladino,et al. Pharmacokinetics of Recombinant Murine Interferon-γ and Human Interferon-αA/D(Bgl) Administered in Concert and Their Influence on Natural Killer Cell Function in Mice , 1988 .
[169] P. Walther,et al. Schedule-dependent enhanced lethality with combined administration of actinomycin D and tumor necrosis factor in mice. , 1989, Journal of biological response modifiers.
[170] T. Nishi,et al. Mutagenesis of human granulocyte colony stimulating factor. , 1989, Biochemical and biophysical research communications.
[171] J. Hannigan,et al. Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[172] Spiegel Rj. The alpha interferons: clinical overview. , 1987 .
[173] R. Armitage,et al. Human IL-7: a novel T cell growth factor. , 1989, Journal of immunology.
[174] H. Deeg,et al. Immunological recovery in 48 patients following syngeneic marrow transplantation or hematological malignancy. , 1982, Transplantation.
[175] D. Longo,et al. Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas. , 1984, Annals of internal medicine.
[176] J. Kolitz,et al. Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2. , 1988, Journal of biological response modifiers.
[177] I. Fidler,et al. The biology of tumor metastasis. , 1989, Seminars in oncology.
[178] R. Schooley,et al. A randomized placebo-controlled trial of recombinant human interferon alpha 2a in patients with aids , 1988 .
[179] S. Rosenberg,et al. Combination Cytokine Immunotherapy with Tumor Necrosis Factor α, Interleukin 2, and α-Interferon and Its Synergistic Antitumor Effects in Mice , 1989 .
[180] E. Gilboa,et al. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. , 1990, Cancer research.
[181] E. Mihich. Future perspectives for biological response modifiers: a viewpoint. , 1986, Seminars in oncology.
[182] K. Zsebo,et al. Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver-conditioned medium , 1990, Cell.
[183] W. Boswell,et al. Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected]. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[184] S. Rosenberg,et al. Intraperitoneal administration of interleukin-2 in patients with cancer. , 1986, Archives of surgery.
[185] J. Villeval,et al. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. , 1988, Blood.
[186] K. Orita,et al. Antitumor effect of recombinant human interferon-beta and interferon-gamma in combination against human colon cancer cell line in vitro and in nude mice. , 1987, Japanese journal of cancer research : Gann.
[187] J. Murray,et al. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[188] J. Talmadge,et al. Correlation of immunomodulatory and therapeutic activities of interferon and interferon inducers in metastatic disease , 1988, Journal of cellular biochemistry.
[189] R. Marcus,et al. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. , 1986, Bone marrow transplantation.
[190] M. Doyle,et al. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. , 1984, Science.
[191] R. Barr,et al. HAEMOPOIETIC ENGRAFTMENT WITH PERIPHERAL BLOOD CELLS IN THE TREATMENT OF MALIGNANT DISEASE , 1982, British journal of haematology.
[192] E. Frei,et al. Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy. , 1987, Cancer research.
[193] R. Hoffmann,et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. , 1988 .
[194] B. Lanske,et al. Interferon-gamma for the treatment of metastatic renal cancer: dose-dependent stimulation and downregulation of beta-2 microglobulin and neopterin responses. , 1987, Immunobiology.
[195] H. Kantarjian,et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. , 1986, The New England journal of medicine.
[196] R. Comolli,et al. Systemic IFN-alpha treatment of multiple bladder papilloma grade I or II patients: pilot study. , 1982, Journal of interferon research.
[197] T. Mosmann,et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. , 1991, Journal of immunology.
[198] E. Kedar,et al. Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematologic disorders. , 1991, Blood.
[199] R. Foà,et al. The inhibitory effect of serum from hairy‐cell leukaemia patients on normal progenitor cells may disappear following prolonged treatment with α‐interferon , 1989 .
[200] B. Vogelstein,et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response , 1990, Cell.
[201] H. Heslop,et al. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. , 1989, Blood.
[202] R. Coombes,et al. Effect of human recombinant tumour necrosis factor and rat gamma interferon on nitrosomethylurea-induced mammary tumours. , 1989, British Journal of Cancer.
[203] M. Toribio,et al. Involvement of the interleukin 4 pathway in the generation of functional gamma delta T cells from human pro-T cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[204] Z. Darżynkiewicz,et al. Effect of recombinant tumor necrosis factor on HL‐60 cells: Cell‐cycle specificity and synergism with actinomycin D , 1987, Journal of cellular physiology.
[205] M. Socinski,et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. , 1988, The New England journal of medicine.
[206] C. Moertel. On lymphokines, cytokines, and breakthroughs. , 1986, JAMA.
[207] C. Eaves,et al. High-efficiency gene transfer to human hematopoietic cells maintained in long-term marrow culture. , 1989, Blood.
[208] R. Abrams,et al. Cyclophosphamide treatment expands the circulating hematopoietic stem cell pool in dogs. , 1981, The Journal of clinical investigation.
[209] R Langer,et al. New methods of drug delivery. , 1990, Science.
[210] G. Marshall,et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. , 1987, The New England journal of medicine.
[211] R. Dutkowski,et al. Eradication of mouse melanoma by combined treatment with recombinant human interleukin 2 and recombinant murine interferon‐gamma , 1988, International journal of cancer.
[212] O. Gurevitch,et al. Self-maintenance ability of circulating hemopoietic stem cells. , 1982, Experimental hematology.
[213] G. Hodgson,et al. Evidence for stem cells in the peripheral blood of mice. , 1962, Blood.
[214] Herberman Rb. Design of clinical trials with biological response modifiers. , 1985 .
[215] I. Fehér,et al. Some properties of the circulating hemopoietic stem cells. , 1974, Blood.
[216] J. Doroshow,et al. A prospective randomized trial of alpha 2B-interferon/gamma-interferon or the combination in advanced metastatic renal cell carcinoma. , 1988, Journal of biological response modifiers.
[217] C. Boucher,et al. CLINICAL AND VIROLOGICAL EFFECTS OF HIGH-DOSE RECOMBINANT INTERFERON-α IN DISSEMINATED AIDS-RELATED KAPOSI'S SARCOMA , 1988, The Lancet.
[218] A. Ganser,et al. Sequential in vivo treatment with two recombinant human hematopoietic growth factors (interleukin-3 and granulocyte-macrophage colony-stimulating factor) as a new therapeutic modality to stimulate hematopoiesis: results of a phase I study. , 1992, Blood.
[219] J. P. Lewis,et al. The repopulating potential and differentiation capacity of hematopoietic stem cells from the blood and bone marrow of normal mice , 1968, Journal of cellular physiology.
[220] F. Ruscetti,et al. Administration of recombinant human interleukin-7 alters the frequency and number of myeloid progenitor cells in the bone marrow and spleen of mice. , 1992, Blood.
[221] S. Mackinnon,et al. Induction of a syngeneic graft-versus-leukemia effect following bone marrow transplantation for chronic myeloid leukemia. , 1990, Leukemia.
[222] R. Shadduck,et al. The effect of recombinant human granulocyte macrophage colony-stimulating factor on neutrophil activation in patients with refractory carcinoma. , 1989, Blood.
[223] M. Revel. The Interferon System in Man: Nature of the Interferon Molecules and Mode of Action , 1984 .
[224] R. Day,et al. A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[225] J. Talmadge,et al. Screening for Biological Response Modifiers: Methods and Rationale , 1985, Developments in Oncology.
[226] V. Carreño,et al. COMBINATION OF RECOMBINANT INTERFERONS ALPHA AND GAMMA IN TREATMENT OF CHRONIC HEPATITIS B , 1987, The Lancet.
[227] P. Scheurich,et al. Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses. , 1987, Journal of immunology.
[228] A. Donnenberg,et al. Selective differentiation and proliferation of hematopoietic cells induced by recombinant human interleukins. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[229] E. Thomas,et al. THE RECOVERY OF LETHALLY IRRADIATED DOGS GIVEN INFUSIONS OF AUTOLOGOUS LEUKOCYTES PRESERVED AT -80 C. , 1964, Blood.
[230] D. Golde,et al. Granulocyte-macrophage colony-stimulating factor enhances neutrophil function in acquired immunodeficiency syndrome patients. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[231] W. Ludwig,et al. Modulation of immune functions by long-term treatment with recombinant interferon-alpha 2 in a patient with hairy-cell leukemia. , 1988, Journal of interferon research.
[232] S. Vedantham,et al. Mechanism of interferon action in hairy cell leukemia: a model of effective cancer biotherapy. , 1992, Cancer research.
[233] J. Ortaldo,et al. Depression of natural killer cytotoxicity after in vivo administration of recombinant leukocyte interferon. , 1983, Journal of immunology.
[234] D. Williams,et al. Retroviral gene transfer of human adenosine deaminase in murine hematopoietic cells: effect of selectable marker sequences on long-term expression. , 1991, Blood.
[235] J. Gutterman,et al. Stimulation of myelopoiesis in patients with aplastic anemia by recombinant human granulocyte-macrophage colony-stimulating factor. , 1988, The New England journal of medicine.
[236] E. Farmer,et al. Acute Graft-vs-Host Disease: Development Following Autologous and Syngeneic Bone Marrow Transplantation , 1987 .
[237] K. Foon,et al. Alpha interferon in the treatment of hematologic malignancies. , 1986, The American journal of medicine.
[238] E. Holmes,et al. Effects of systemic recombinant interleukin-2 on natural killer and lymphokine activated killer activity of human tumor infiltrating lymphocytes. , 1988, Cancer research.
[239] K. Bhalla,et al. The effect of recombinant human granulocyte-macrophage colony-stimulating factor (rGM-CSF) on 3'-azido-3'-deoxythimidine (AZT)-mediated biochemical and cytotoxic effects on normal human myeloid progenitor cells , 1989 .
[240] K. Sullivan,et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. , 1981, The New England journal of medicine.
[241] P W Mansell,et al. Pharmacokinetics of recombinant interleukin 2 in humans. , 1990, Cancer research.
[242] W. Nothdurft,et al. Studies on the regeneration of the CFU-C population in blood and bone marrow of lethally irradiated dogs after autologous transfusion of cryopreserved mononuclear blood cells. , 2009, Scandinavian journal of haematology.
[243] S. Agarwal,et al. Letter: Alpha-fetoprotein in Indian childhood cirrhosis. , 1974, Lancet.
[244] D. Blaise,et al. IMPACT OF T-CELL DEPLETION ON OUTCOME OF ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR STANDARD-RISK LEUKAEMIAS , 1987, The Lancet.
[245] L. Baldini,et al. Human recombinant interferon alpha-2C enhances the expression of class II HLA antigens on hairy cells. , 1986, Blood.
[246] H. Nakauchi,et al. Synergistic effect of IL-3 and IL-6 on highly enriched murine hemopoietic progenitors. , 1992, Experimental hematology.
[247] M. Martelli,et al. Imbalances within the peripheral blood T-helper (CD4+) and T-suppressor (CD8+) cell populations in the reconstitution phase after human bone marrow transplantation. , 1988, Blood.
[248] J. Johnson,et al. Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck. , 1987, Cancer research.
[249] W. Franklin,et al. Is there a direct differentiation‐inducing effect of human recombinant interferon on hairy cell leukemia in vitro? , 1989, Cancer.
[250] E. Kleinerman,et al. Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with human recombinant gamma-interferon. , 1986, Cancer research.
[251] K. Cantell,et al. Preparation of human leukocyte interferon for clinical use. , 1977, Texas reports on biology and medicine.
[253] G. Pizza,et al. Tumour regression after intralesional injection of interleukin 2 (IL‐2) in bladder cancer. Preliminary report , 1984, International journal of cancer.
[254] M. Green,et al. EFFECT OF GRANULOCYTE COLONY STIMULATING FACTOR ON NEUTROPENIA INDUCED BY CYTOTOXIC CHEMOTHERAPY , 1988, The Lancet.
[255] A. Fefer,et al. Very low dose alpha-2b interferon for the treatment of hairy cell leukemia [see comments] , 1989 .
[256] L. Itri,et al. Safety and tolerance of recombinant interferon alfa‐2a (roferon®‐A) in Cancer Patients , 1986, Cancer.
[257] E. Hersh,et al. Treatment of hairy cell leukemia with alpha interferons , 1986, Cancer.
[258] R. Cameron,et al. Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases. , 1988, Cancer research.
[259] Oldham Rk. Biologicals and biological response modifiers: fourth modality of cancer treatment. , 1984 .
[260] K. Tsang,et al. Induction of interleukin 2 receptor (TAC) by tumor necrosis factor in YT cells. , 1987, Journal of immunology.
[261] E. Baysal,et al. An IVS‐I‐117 (G→A) acceptor splice site mutation in the α 1‐globin gene is a nondeletional α‐thalassaemia‐2 determinant in an Indian population , 1993 .
[262] P. Leder,et al. Murine interleukin-4 displays potent anti-tumor activity in vivo , 1989, Cell.
[263] P. Bunn,et al. The role of recombinant interferon alfa‐2a in the therapy of cutaneous t‐cell lymphomas , 1986, Cancer.
[264] E. Gilboa,et al. Retroviral vector-mediated high-efficiency expression of adenosine deaminase (ADA) in hematopoietic long-term cultures of ADA-deficient marrow cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[265] H. Muss. Interferon therapy for renal cell carcinoma. , 1987, Seminars in oncology.
[266] R. Foà,et al. Effect of alpha-interferon on the immune system of patients with hairy cell leukemia. , 1987, Leukemia.
[267] P. Fisher,et al. Increased surface expression and shedding of tumor associated antigens by human breast carcinoma cells treated with recombinant human interferons or phorbol ester tumor promoters. , 1989, Anticancer research.
[268] D. Longo,et al. The determination of an immunologically active dose of interferon-gamma in patients with melanoma. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[269] G. Forni,et al. Tumor immunotherapy by local injection of interleukin 2 and non-reactive lymphocytes. Experimental and clinical results. , 1988, Progress in experimental tumor research.
[270] J. Gutterman,et al. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. , 1987, The New England journal of medicine.
[271] R. Bechhofer,et al. Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer. , 1988, Cancer research.
[272] D. Reece,et al. Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse [corrected] [published erratum appears in Blood 1992 Jun 15;79(12):3397] , 1991 .
[273] T. Hopp,et al. Lymphokines: from conjecture to the clinic. , 1986, Seminars in oncology.
[274] S. Salmon,et al. Phase I-II Trial of Interferon-α2b by Continuous Subcutaneous Infusion over 28 Days , 1988 .
[275] A. Huang,et al. Changes in hairy cells after alpha-interferon treatment as measured by flow cytometry. , 1987, Leukemia.
[276] R. Hoffman,et al. Growth factors affecting human thrombocytopoiesis: potential agents for the treatment of thrombocytopenia. , 1992, Blood.
[277] J. Gutterman,et al. Stimulation of hematopoiesis in patients with bone marrow failure and in patients with malignancy by recombinant human granulocyte-macrophage colony-stimulating factor. , 1988, Blood.
[278] M. Merino,et al. Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha. , 1988, Cancer research.
[279] J. Watson,et al. Effect of IL-7 on the growth of fetal thymocytes in culture. , 1989, Journal of immunology.
[280] S. Fosså,et al. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study. , 1989, European journal of cancer & clinical oncology.
[281] R. Herberman. Interleukin-2 therapy of human cancer: potential benefits versus toxicity. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[282] David A. Williams,et al. Long-term expression of human adenosine deaminase in mice transplanted with retrovirus-infected hematopoietic stem cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[283] David A. Williams,et al. Stem Cell Factor, Interleukin-3, and Interleukin-6 Promote Retroviral-Mediated Gene Transfer Into Murine Hematopoietic Stem Cells , 1992 .